Platform-Powered Oncology Drug Development
Platform-Powered Oncology Drug Development
Platform-Powered Oncology Drug Development
Transforming the Future of Cancer Treatment
Transforming Cancer Treatment Through Pioneering Science
Transforming Cancer Treatment Through Pioneering Science
Transforming Cancer Treatment Through Pioneering Science
(About Us)
7 Primus Biosciences is an innovative oncology biotech distinguished by proprietary platforms and deep translational expertise. Our accomplished team transforms cutting-edge discoveries into advanced cancer therapies combining world-class scientific insight with breakthrough technology to deliver real hope for patients globally.
By partnering with leading academic and industry collaborators, we accelerate a robust pipeline designed to redefine cancer care and unlock exceptional value for stakeholders.
(About Us)
7 Primus Biosciences is an innovative oncology biotech distinguished by proprietary platforms and deep translational expertise. Our accomplished team transforms cutting-edge discoveries into advanced cancer therapies combining world-class scientific insight with breakthrough technology to deliver real hope for patients globally.
By partnering with leading academic and industry collaborators, we accelerate a robust pipeline designed to redefine cancer care and unlock exceptional value for stakeholders.
(About Us)
7 Primus Biosciences is an innovative oncology biotech distinguished by proprietary platforms and deep translational expertise. Our accomplished team transforms cutting-edge discoveries into advanced cancer therapies combining world-class scientific insight with breakthrough technology to deliver real hope for patients globally.
By partnering with leading academic and industry collaborators, we accelerate a robust pipeline designed to redefine cancer care and unlock exceptional value for stakeholders.
Innovations in Targeted Oncology
Inducing Cancer Cell Death Through BAK Activation
CombYSelect Platform for Efficient IgG Heterodimerization
Bispecific Antibody and Bispecific Antibody-Drug Conjugates
We are developing 7PB-100, a novel small molecule BAK activator designed to selectively induce apoptosis in tumors with high BAK expression. Preclinical studies demonstrate marked tumor suppression with minimal impact on normal tissues, highlighting its potential as both a standalone treatment and a synergistic agent in combination therapies.
The CombYSelect platform accelerates the creation of highly stable IgG heterodimers for next-generation bispecific antibodies and bispecific antibody-drug conjugates (BADCs). This proprietary, in silico, structure-guided approach produces long-lasting, functionally enhanced molecules capable of dual-targeting key cancer antigens, facilitating therapy customization and rapid pipeline expansion.
Through our proprietary CombYSelect platform, we create IgG-like bispecific antibodies that precisely target multiple tumor antigens for greater selectivity and sustained efficacy. Our bispecific ADCs (BADCs) combine these antibodies with various payloads, including 7PB-100, to enhance cancer targeting, minimize antigen escape, and reduce toxicity compared to conventional ADCs.
Innovations in Targeted Oncology
Inducing Cancer Cell Death Through BAK Activation
CombYSelect Platform for Efficient IgG Heterodimerization
Bispecific Antibody and Bispecific Antibody-Drug Conjugates
We are developing 7PB-100, a novel small molecule BAK activator designed to selectively induce apoptosis in tumors with high BAK expression. Preclinical studies demonstrate marked tumor suppression with minimal impact on normal tissues, highlighting its potential as both a standalone treatment and a synergistic agent in combination therapies.
The CombYSelect platform accelerates the creation of highly stable IgG heterodimers for next-generation bispecific antibodies and bispecific antibody-drug conjugates (BADCs). This proprietary, in silico, structure-guided approach produces long-lasting, functionally enhanced molecules capable of dual-targeting key cancer antigens, facilitating therapy customization and rapid pipeline expansion.
Through our proprietary CombYSelect platform, we create IgG-like bispecific antibodies that precisely target multiple tumor antigens for greater selectivity and sustained efficacy. Our bispecific ADCs (BADCs) combine these antibodies with various payloads, including 7PB-100, to enhance cancer targeting, minimize antigen escape, and reduce toxicity compared to conventional ADCs.
Innovations in Targeted Oncology
Inducing Cancer Cell Death Through BAK Activation
CombYSelect Platform for Efficient IgG Heterodimerization
Bispecific Antibody and Bispecific Antibody-Drug Conjugates
We are developing 7PB-100, a novel small molecule BAK activator designed to selectively induce apoptosis in tumors with high BAK expression. Preclinical studies demonstrate marked tumor suppression with minimal impact on normal tissues, highlighting its potential as both a standalone treatment and a synergistic agent in combination therapies.
The CombYSelect platform accelerates the creation of highly stable IgG heterodimers for next-generation bispecific antibodies and bispecific antibody-drug conjugates (BADCs). This proprietary, in silico, structure-guided approach produces long-lasting, functionally enhanced molecules capable of dual-targeting key cancer antigens, facilitating therapy customization and rapid pipeline expansion.
Through our proprietary CombYSelect platform, we create IgG-like bispecific antibodies that precisely target multiple tumor antigens for greater selectivity and sustained efficacy. Our bispecific ADCs (BADCs) combine these antibodies with various payloads, including 7PB-100, to enhance cancer targeting, minimize antigen escape, and reduce toxicity compared to conventional ADCs.
Leading the Future of Cancer Medicine
Leading the Future of Cancer Medicine
Our robust pipeline spans first-in-class small molecules, advanced bispecifics, and BADCs, each program designed to address high unmet needs and unlock new standards in oncology.
7PB-100
A first-in-class small molecule BAK activator designed for potent anti-tumor efficacy and minimal impact on normal cells.
7PB-200
IgG1-format bispecific antibody targeting undisclosed tumor-associated antigens (TAAs).
7PB-300
Bispecific antibody-drug conjugate combining dual targeting with precise payload delivery.
7PB-100
A first-in-class small molecule BAK activator designed for potent anti-tumor efficacy and minimal impact on normal cells.
7PB-200
IgG1-format bispecific antibody targeting undisclosed tumor-associated antigens (TAAs).
7PB-300
Bispecific antibody-drug conjugate combining dual targeting with precise payload delivery.
7PB-100
A first-in-class small molecule BAK activator designed for potent anti-tumor efficacy and minimal impact on normal cells.
7PB-200
IgG1-format bispecific antibody targeting undisclosed tumor-associated antigens (TAAs).
7PB-300
Bispecific antibody-drug conjugate combining dual targeting with precise payload delivery.
Our Strengths
Diverse R&D Programs
CombySelect Platform
Rigorous R&D Evaluation
Biomarker-Driven Patient Selection
Strategic Collaboration Network
Patient-Centered Philosophy
Your Gateway to Precision Cancer Innovation
Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.
Interested in unlocking new possibilities? Connect with our team.
Let’s Talk With Us
Your Gateway to Precision Cancer Innovation
Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.
Interested in unlocking new possibilities? Connect with our team.
Let’s Talk With Us
Your Gateway to Precision Cancer Innovation
Let’s Talk With Us
Interested in unlocking new possibilities? Connect with our team.